Rheumatoid Arthritis Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, France, China - Size and Forecast 2024-2028

1 Executive Summary

• 1.1 Market overview
  • Exhibit 01: Executive Summary – Chart on Market Overview
  • Exhibit 02: Executive Summary – Data Table on Market Overview
  • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary – Chart on Market by Geography
  • Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
  • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
  • Exhibit 07: Executive Summary – Chart on Incremental Growth
  • Exhibit 08: Executive Summary – Data Table on Incremental Growth
  • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
  • Exhibit 13: Market segments

• 3.3 Market size 2023

• 3.4 Market outlook: Forecast for 2023-2028
  • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global rheumatoid arthritis drugs market 2018 - 2022
  • Exhibit 18: Historic Market Size – Data Table on global rheumatoid arthritis drugs market 2018 - 2022 ($ billion)

• 4.2 Drug Class Segment Analysis 2018 - 2022
  • Exhibit 19: Historic Market Size – Drug Class Segment 2018 - 2022 ($ billion)

• 4.3 Type Segment Analysis 2018 - 2022
  • Exhibit 20: Historic Market Size – Type Segment 2018 - 2022 ($ billion)

• 4.4 Geography Segment Analysis 2018 - 2022
  • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

• 4.5 Country Segment Analysis 2018 - 2022
  • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

• 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

• 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

• 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

• 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

• 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

• 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

• 6.1 Market segments
  • Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
  • Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)

• 6.2 Comparison by Drug Class
  • Exhibit 32: Chart on Comparison by Drug Class
  • Exhibit 33: Data Table on Comparison by Drug Class

• 6.3 Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028
  • Exhibit 34: Chart on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 35: Data Table on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 36: Chart on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
  • Exhibit 37: Data Table on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)

• 6.4 Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028
  • Exhibit 38: Chart on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 39: Data Table on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 40: Chart on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
  • Exhibit 41: Data Table on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)

• 6.5 Corticosteroids - Market size and forecast 2023-2028
  • Exhibit 42: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 43: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 44: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
  • Exhibit 45: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)

• 6.6 Market opportunity by Drug Class
  • Exhibit 46: Market opportunity by Drug Class ($ billion)
  • Exhibit 47: Data Table on Market opportunity by Drug Class ($ billion)

7 Market Segmentation by Type

• 7.1 Market segments
  • Exhibit 48: Chart on Type - Market share 2023-2028 (%)
  • Exhibit 49: Data Table on Type - Market share 2023-2028 (%)

• 7.2 Comparison by Type
  • Exhibit 50: Chart on Comparison by Type
  • Exhibit 51: Data Table on Comparison by Type

• 7.3 Biologics - Market size and forecast 2023-2028
  • Exhibit 52: Chart on Biologics - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 53: Data Table on Biologics - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 54: Chart on Biologics - Year-over-year growth 2023-2028 (%)
  • Exhibit 55: Data Table on Biologics - Year-over-year growth 2023-2028 (%)

• 7.4 Small Molecules - Market size and forecast 2023-2028
  • Exhibit 56: Chart on Small Molecules - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 57: Data Table on Small Molecules - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 58: Chart on Small Molecules - Year-over-year growth 2023-2028 (%)
  • Exhibit 59: Data Table on Small Molecules - Year-over-year growth 2023-2028 (%)

• 7.5 Market opportunity by Type
  • Exhibit 60: Market opportunity by Type ($ billion)
  • Exhibit 61: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview
  • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
  • Exhibit 63: Chart on Market share by geography 2023-2028 (%)
  • Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

• 9.2 Geographic comparison
  • Exhibit 65: Chart on Geographic comparison
  • Exhibit 66: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2023-2028
  • Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)

• 9.4 Europe - Market size and forecast 2023-2028
  • Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)

• 9.5 Asia - Market size and forecast 2023-2028
  • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

• 9.7 US - Market size and forecast 2023-2028
  • Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

• 9.8 UK - Market size and forecast 2023-2028
  • Exhibit 87: Chart on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 88: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 89: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibit 90: Data Table on UK - Year-over-year growth 2023-2028 (%)

• 9.9 China - Market size and forecast 2023-2028
  • Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)

• 9.10 Germany - Market size and forecast 2023-2028
  • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)

• 9.11 France - Market size and forecast 2023-2028
  • Exhibit 99: Chart on France - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 100: Data Table on France - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 101: Chart on France - Year-over-year growth 2023-2028 (%)
  • Exhibit 102: Data Table on France - Year-over-year growth 2023-2028 (%)

• 9.12 Market opportunity by geography
  • Exhibit 103: Market opportunity by geography ($ billion)
  • Exhibit 104: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges
  • Exhibit 105: Impact of drivers and challenges in 2023 and 2028

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
  • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
  • Exhibit 107: Overview on factors of disruption

• 11.4 Industry risks
  • Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
  • Exhibit 109: Vendors covered

• 12.2 Market positioning of vendors
  • Exhibit 110: Matrix on vendor position and classification

• 12.3 AbbVie Inc.
  • Exhibit 111: AbbVie Inc. - Overview
  • Exhibit 112: AbbVie Inc. - Product / Service
  • Exhibit 113: AbbVie Inc. - Key news
  • Exhibit 114: AbbVie Inc. - Key offerings

• 12.4 Amgen Inc.
  • Exhibit 115: Amgen Inc. - Overview
  • Exhibit 116: Amgen Inc. - Product / Service
  • Exhibit 117: Amgen Inc. - Key offerings

• 12.5 Bristol Myers Squibb Co.
  • Exhibit 118: Bristol Myers Squibb Co. - Overview
  • Exhibit 119: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 120: Bristol Myers Squibb Co. - Key news
  • Exhibit 121: Bristol Myers Squibb Co. - Key offerings

• 12.6 Eli Lilly and Co.
  • Exhibit 122: Eli Lilly and Co. - Overview
  • Exhibit 123: Eli Lilly and Co. - Product / Service
  • Exhibit 124: Eli Lilly and Co. - Key news
  • Exhibit 125: Eli Lilly and Co. - Key offerings

• 12.7 F. Hoffmann La Roche Ltd.
  • Exhibit 126: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 127: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 128: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 129: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 130: F. Hoffmann La Roche Ltd. - Segment focus

• 12.8 Genor Biopharma Holdings Ltd.
  • Exhibit 131: Genor Biopharma Holdings Ltd. - Overview
  • Exhibit 132: Genor Biopharma Holdings Ltd. - Product / Service
  • Exhibit 133: Genor Biopharma Holdings Ltd. - Key offerings

• 12.9 Gilead Sciences Inc.
  • Exhibit 134: Gilead Sciences Inc. - Overview
  • Exhibit 135: Gilead Sciences Inc. - Product / Service
  • Exhibit 136: Gilead Sciences Inc. - Key news
  • Exhibit 137: Gilead Sciences Inc. - Key offerings

• 12.10 Johnson and Johnson
  • Exhibit 138: Johnson and Johnson - Overview
  • Exhibit 139: Johnson and Johnson - Business segments
  • Exhibit 140: Johnson and Johnson - Key news
  • Exhibit 141: Johnson and Johnson - Key offerings
  • Exhibit 142: Johnson and Johnson - Segment focus

• 12.11 Kangstem Biotech Co. Ltd.
  • Exhibit 143: Kangstem Biotech Co. Ltd. - Overview
  • Exhibit 144: Kangstem Biotech Co. Ltd. - Product / Service
  • Exhibit 145: Kangstem Biotech Co. Ltd. - Key offerings

• 12.12 Novartis AG
  • Exhibit 146: Novartis AG - Overview
  • Exhibit 147: Novartis AG - Business segments
  • Exhibit 148: Novartis AG - Key offerings
  • Exhibit 149: Novartis AG - Segment focus

• 12.13 Oryn Therapeutics
  • Exhibit 150: Oryn Therapeutics - Overview
  • Exhibit 151: Oryn Therapeutics - Product / Service
  • Exhibit 152: Oryn Therapeutics - Key offerings

• 12.14 Pfizer Inc.
  • Exhibit 153: Pfizer Inc. - Overview
  • Exhibit 154: Pfizer Inc. - Product / Service
  • Exhibit 155: Pfizer Inc. - Key news
  • Exhibit 156: Pfizer Inc. - Key offerings

• 12.15 Sanofi
  • Exhibit 157: Sanofi - Overview
  • Exhibit 158: Sanofi - Business segments
  • Exhibit 159: Sanofi - Key news
  • Exhibit 160: Sanofi - Key offerings
  • Exhibit 161: Sanofi - Segment focus

• 12.16 Sorrento Therapeutics Inc.
  • Exhibit 162: Sorrento Therapeutics Inc. - Overview
  • Exhibit 163: Sorrento Therapeutics Inc. - Business segments
  • Exhibit 164: Sorrento Therapeutics Inc. - Key offerings
  • Exhibit 165: Sorrento Therapeutics Inc. - Segment focus

• 12.17 UCB SA
  • Exhibit 166: UCB SA - Overview
  • Exhibit 167: UCB SA - Product / Service
  • Exhibit 168: UCB SA - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist
  • Exhibit 169: Inclusions checklist
  • Exhibit 170: Exclusions checklist

• 13.3 Currency conversion rates for US$
  • Exhibit 171: Currency conversion rates for US$

• 13.4 Research methodology
  • Exhibit 172: Research methodology
  • Exhibit 173: Validation techniques employed for market sizing
  • Exhibit 174: Information sources

• 13.5 List of abbreviations
  • Exhibit 175: List of abbreviations